Tech Company Financing Transactions
DNAtriX Funding Round
DNAtriX secured a $15.5 million funding round on 9/26/2018. Backers included private investors.
Transaction Overview
Company Name
Announced On
9/26/2018
Transaction Type
Venture Equity
Amount
$15,529,295
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. 40 investors participated in the offering. The amount may include options, warrants or other securities. Contact technology company for investment details, if applicable. Not an offer or solicitation for the sale of securities or debt. SEC regulatory filing.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2450 Holcombe Blvd. X 200
Houston, TX 77021
USA
Houston, TX 77021
USA
Phone
Website
Email Address
Overview
DNAtrix is a clinical stage, biotechnology company developing virus-driven immunotherapies for cancer. DNAtrix s lead product, DNX-2401, is a modified common cold virus that targets and kills cancer cells selectively.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Frank Tufaro
Chief Financial Officer
Brian Mooney
VP - Bus. Development
Brett Ewald
VP - Manufacturing
Erin Mitchell
VP - R & D
Karen Gammon
VP - R & D
Imre Kovesdi
VP - R & D
Joan Robbins
Browse more venture capital transactions:
Prev: 9/26/2018: GigaIO venture capital transaction
Next: 9/26/2018: SenseHawk venture capital transaction
Share this article
About Database of VC Transactions
Our team works diligently to report on funding rounds that are announced publicly. VC investment data records on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs